When serum IGFBP-2 and anti-IGFBP-2 antibodies were detected simultaneously, the sensitivity of the assay was raised to 85.7%, and the specificity was 57.5% indicating that use of both serum IGFBP2 and anti-IGFBP-2 antibody can increase the diagnostic efficacy in lung cancer. This evidence concerns the gene IGFBP2 and lung cancer.